Page last updated: 2024-11-13
per977
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
PER977: a factor Xa inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 71576543 |
| CHEMBL ID | 3544919 |
| SCHEMBL ID | 14985871 |
| MeSH ID | M000600479 |
Synonyms (29)
| Synonym |
|---|
| SCHEMBL14985871 |
| unii-u2r67kv65q |
| per 977 |
| n1,n1'-(piperazine-1,4-diylbis(propane-1,3-diyl))bis-l-argininamide |
| u2r67kv65q , |
| ciraparantag |
| per977 |
| pentanamide, n,n'-(1,4-piperazinediyldi-3,1-propanediyl)bis(2-amino-5-((aminoiminomethyl)amino)-, (2s,2's)- |
| per-977 |
| 1438492-26-2 |
| aripazine |
| ciraparantag [usan] |
| ciraparantag [who-dd] |
| ciraparantag [inn] |
| CHEMBL3544919 |
| HY-18660 |
| AKOS030526536 |
| CS-5640 |
| ciraparantag (usan) |
| D10868 |
| ciraparantag(per977) |
| DB15199 |
| Q27290602 |
| (2s,2's)-n,n'-(piperazine-1,4-diylbis(propane-3,1-diyl))bis(2-amino-5-guanidinopentanamide) |
| 1438492-26-2 (free base) |
| (2s)-2-amino-n-[3-[4-[3-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propyl]piperazin-1-yl]propyl]-5-(diaminomethylideneamino)pentanamide |
| pentanamide, n,n'-(1,4-piperazinediyldi-3,1-propanediyl)bis[2-amino-5-[(aminoiminomethyl)amino]-, (2s,2's)- |
| (2s)-2-amino-n-[3-(4-{3-[(2s)-2-amino-5-carbamimidamidopentanamido]propyl}piperazin-1-yl)propyl]-5-carbamimidamidopentanamide |
| DTXSID701045783 |
Research Excerpts
Toxicity
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Ciraparantag reaches maximum concentration within minutes after IV administration with a half-life of 12 to 19 minutes." | ( Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants. Ansell, J; Baker, C; Bakhru, SH; Burnett, A; Chen, L; Jiang, X; Laulicht, BE; Steiner, S; Villano, S, 2021) | 0.62 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Nonetheless, the absence of the ability for clinicians to assess compliance or washout with a simple laboratory test (or to adjust dosing with a similar assessment) and the absence of an antidote to rapidly stop major hemorrhage or to enhance safety in the setting of emergent or urgent surgery/procedures have been limitations to greater non-vitamin K antagonist oral anticoagulant usage and better thromboembolic prevention." | ( NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. Kaminskas, E; Reiffel, JA; Reilly, P; Sager, P; Sarich, T; Seltzer, J; Weitz, JI, 2016) | 0.43 |
| " In addition to familiarity with the dosing and monitoring of vitamin K antagonists, clinicians are accustomed to using vitamin K if there is a need to reverse the anticoagulant effect of vitamin K antagonists." | ( Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents. Antman, EM; Giugliano, RP; Ruff, CT, 2016) | 0.43 |
| "Ciraparantag provides a dose-related reversal of anticoagulation induced by steady-state dosing of apixaban or rivaroxaban." | ( Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects. Ansell, J; Bakhru, S; Freedman, D; Laulicht, BE; Tracey, G; Villano, S, 2022) | 0.72 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (2)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1823248 | Binding affinity to heparin (unknown origin) assessed as apparent dissociation constant by SPR assay | 2022 | Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6 | Dynamic Combinatorial Optimization of |
| AID1823251 | Inhibition of heparin (unknown origin) assessed as reversal of heparin reduced FXa protease activity by measuring Z-D-LGR-N(Me)ANBA peptide substrate at 1 uM hydrolysis after 30 mins | 2022 | Journal of medicinal chemistry, 03-24, Volume: 65, Issue:6 | Dynamic Combinatorial Optimization of |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (45)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 37 (82.22) | 24.3611 |
| 2020's | 8 (17.78) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 18.28
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.28) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (6.52%) | 5.53% |
| Reviews | 31 (67.39%) | 6.00% |
| Case Studies | 1 (2.17%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (23.91%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||